Safety of quadrivalent human papillomavirus vaccine

Journal of Internal Medicine

Volumn 271, Issue 2, 2012, Pages 177-178

  Omer, S B ^a,b  

^a EMORY UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

APPENDICITIS; AUTOIMMUNITY; CANCER IMMUNIZATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROENTERITIS; GRAVES DISEASE; HASHIMOTO DISEASE; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; NAUSEA; NOTE; PELVIC INFLAMMATORY DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PRURITUS; SYNCOPE; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES;

EID: 84855918565     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02481.x     Document Type: Note

References (10)

1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion. Cancer Among Women. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, 2011. 2-10-2011, 10-20-2011. Accessed on 15 November 2011 at
2. World Health Organization. Human Papillomavirus and HPV Vaccines: Technical Information for Policy-Makers and Health Professionals. Geneva: World Health Organization, 2007.
3. Chao C, Klein NP, Velicer CM et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 2011 October 4. doi:10.1111/j.1365-2796.2011.02467.x. (Epub ahead of print).
4. Merck & Co., Inc. GARDASIL Package Insert. 11. Whitehouse Station: Merck & Co., Inc, 2011.
5. CDC/National Center for Health Statistics. Death Rates by 10-Year Age Groups: United States and Each State, 1999-2007. Atlanta: CDC/National Center for Health Statistics, 2011. 10-8-2010, 10-20-2011.
6. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) & Division of Healthcare Quality Promotion (DHQP). Frequently Asked Questions about HPV Vaccine Safety. Atlanta: Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) & Division of Healthcare Quality Promotion (DHQP), 2011. 8-8-2011, 10-20-2011.
7. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750-7.
8. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28: 4731-7.
9. Bonanni P, Cohet C, Kjaer SK et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010; 28: 4719-30.
10. National and state vaccination coverage among adolescents aged 13 through 17years - United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 1117-23.